Erythropoietin and Its Angiogenic Activity
AbstractErythropoietin (EPO) is the main hematopoietic hormone acting on progenitor red blood cells via stimulation of cell growth, differentiation, and anti-apoptosis. However, its receptor (EPOR) is also expressed in various non-hematopoietic tissues, including endothelium. EPO is a pleiotropic growth factor that exhibits growth stimulation and cell/tissue protection on numerous cells and tissues. In this article we review the angiogenesis potential of EPO on endothelial cells in heart, brain, and leg ischemia, as well as its role in retinopathy protection and tumor promotion. Furthermore, the effect of EPO on bone marrow and adipose tissue is also discussed. View Full-Text
Share & Cite This Article
Kimáková, P.; Solár, P.; Solárová, Z.; Komel, R.; Debeljak, N. Erythropoietin and Its Angiogenic Activity. Int. J. Mol. Sci. 2017, 18, 1519.
Kimáková P, Solár P, Solárová Z, Komel R, Debeljak N. Erythropoietin and Its Angiogenic Activity. International Journal of Molecular Sciences. 2017; 18(7):1519.Chicago/Turabian Style
Kimáková, Patrícia; Solár, Peter; Solárová, Zuzana; Komel, Radovan; Debeljak, Nataša. 2017. "Erythropoietin and Its Angiogenic Activity." Int. J. Mol. Sci. 18, no. 7: 1519.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.